Skip to content

Evaluation of a Question Prompt List for Patients With Myelodysplastic Syndromes (QPL-MDS)

Evaluation of a Question Prompt List for Patients With Myelodysplastic Syndromes (QPL-MDS)

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02781441
Acronym
QPL-MDS
Enrollment
140
Registered
2016-05-24
Start date
2016-04-30
Completion date
2018-09-30
Last updated
2017-09-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myelodysplastic Syndromes

Brief summary

MDS are a diverse group of hematopoietic malignancies, which mainly occur in patients over 75 years of age. Incidence rate in 2012 in France was more than 6 cases per 100 000 person-years. MDS are characterized by ineffective haematopoiesis causing cytopenia, and by leukemic transformation. The disease is heterogeneous, its pathophysiology complex and clinical evolution variable.The few data available on MDS patients show how difficult it is to understand MDS, its prognosis and the reasons for prescribing or not some treatments. In the context of a highly complex potentially lethal disease such as MDS, it is of utmost importance to optimize the information conveyed to patients. Particularly, 70.5% of MDS patients surveyed in our developmental study would have preferred more information about prognosis at diagnosis disclosure. A simple intervention based on the use of a question prompt list (QPL), would greatly improve the information process by helping patients to express their main concerns at their medical consultations. Cultural differences may exist in the appraisal of QPLs and QPLs have not yet been widely used in France. However, in line with the previous results available in the literature and in a context a priori favourable to the use of such an instrument, the investigators hypothesise that use of a QPL will increase MDS patients' expressions of concerns and questions at their medical consultations. Particularly the investigators assume that the discussion about prognosis will be facilitated, without increasing anxiety because patients remain free to ask or not for such information. The use of QPLs would also be a way to limit social inequalities related to insufficient information and to encourage patient-doctor communication and meeting of patient preferences which could lead to better health outcomes.

Interventions

BEHAVIORALEducation brochure of Groupe Français des Myélodysplasies

Sponsors

Institut Paoli-Calmettes
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients newly referred for a MDS in one of the participating centres * Older than 18 * Able to answer a self-administered questionnaire * Having signed an informed consent * affiliated to the French Social Security System

Exclusion criteria

* emergency,patients deprived of liberty or placed under the authority of a tutor

Design outcomes

Primary

MeasureTime frameDescription
Patients having discussed as they wished about the prognosis of their MDS in the next medical consultation17 monthsThe discussion about prognosis will be collected through the audiotaping of the consultation.

Secondary

MeasureTime frameDescription
number of questions and concerns expressed in each content category covered by the QPL (including prognosis)17 monthsData collected through the audiotaping of the consultation
Duration of the recorded consultation17 monthsData collected through the audiotaping of the consultation
Quality of life17 monthsQuestionnaire
Anxiety17 monthsQuestionnaire
Satisfaction with the provided information17 monthsQuestionnaire

Countries

France

Contacts

Primary ContactDominique GENRE, MD
drci.up@ipc.unicancer.fr0033491223778
Backup ContactJihane PAKRADOUNI, PharmD PhD
drci.up@ipc.unicancer.fr0033491223778

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026